Esophageal cancer is the sixth most common cause of cancer death worldwide, with about 20,000 new cases diagnosed in the U.S. each year. Treatment typically combines surgery, radiation, and chemotherapy, and newer immunotherapy drugs have extended survival for some people with advanced disease.
What's actually going on in research
Trials are testing checkpoint inhibitors like nivolumab and pembrolizumab in earlier stages of disease, targeted drugs for HER2-positive tumors, and combinations that might make immunotherapy work for more people. Researchers are also studying less invasive surgical techniques, better ways to detect cancer early, and treatments tailored to whether the tumor is adenocarcinoma or squamous cell type.
Immunotherapy moving earlier
Checkpoint inhibitors already approved for advanced esophageal cancer are now being tested before or after surgery. Early results suggest they may help prevent recurrence when given alongside chemotherapy.
HER2-targeted therapy
About 20 percent of esophageal cancers overexpress HER2, the same protein targeted in some breast cancers. Trials are testing trastuzumab and newer antibody-drug conjugates in this subset of patients.
Minimal surgery approaches
Studies are comparing traditional open surgery to minimally invasive and robot-assisted techniques. The goal is to achieve the same cancer control with shorter recovery and fewer complications.
What to know before you search
Eligibility typically depends on cancer stage, tumor type (adenocarcinoma or squamous cell), HER2 and PD-L1 status, prior treatments, and whether the cancer can be surgically removed.
What types of trials are currently open
- Neoadjuvant trials — Testing chemotherapy, radiation, or immunotherapy given before surgery to shrink tumors and improve surgical outcomes.
- Adjuvant trials — Testing treatments given after surgery to reduce the chance of cancer returning.
- Advanced disease trials — Testing new drugs or combinations for cancer that has spread or cannot be removed with surgery.
- Targeted therapy trials — Testing drugs matched to specific tumor features like HER2 status or other biomarkers.
- Surgical technique trials — Comparing different surgical approaches to see which offers better recovery and long-term outcomes.
Recently added Esophageal Cancer trials
Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
This is a Phase II Study of Candonilimab Combined with Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
Find Esophageal Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.